PHG vs. SNY: A Head-to-Head Stock Comparison
Updated onHere’s a clear look at PHG and SNY, comparing key factors like historical performance, profitability, financial strength, growth, dividend, and valuation.
Company Profile
Both PHG and SNY offer U.S. investors access to foreign companies, with PHG trading as New York Registered Shares and SNY as an American Depositary Receipt (ADR).
| Symbol | PHG | SNY |
|---|---|---|
| Company Name | Koninklijke Philips N.V. | Sanofi |
| Country | Netherlands | France |
| GICS Sector | Health Care | Health Care |
| GICS Industry | Health Care Equipment & Supplies | Pharmaceuticals |
| Market Capitalization | 26.43 billion USD | 123.24 billion USD |
| Exchange | NYSE | NasdaqGS |
| Listing Date | March 17, 1980 | July 1, 2002 |
| Security Type | NY Reg Shrs | ADR |
Historical Performance
This chart compares the performance of PHG and SNY by tracking the growth of an initial $10,000 investment in each. Use the tabs to select the desired time period. Data is adjusted for dividends and splits.
Historical Performance at a Glance
| Symbol | PHG | SNY |
|---|---|---|
| 5-Day Price Return | 1.54% | 3.98% |
| 13-Week Price Return | 12.47% | -7.74% |
| 26-Week Price Return | -12.21% | -16.60% |
| 52-Week Price Return | -11.79% | -13.80% |
| Month-to-Date Return | 2.68% | 9.70% |
| Year-to-Date Return | -2.79% | -7.73% |
| 10-Day Avg. Volume | 1.10M | 1.63M |
| 3-Month Avg. Volume | 1.84M | 2.04M |
| 3-Month Volatility | 28.64% | 24.79% |
| Beta | 1.05 | 0.72 |
Profitability
Return on Equity (TTM)
PHG
-0.18%
Health Care Equipment & Supplies Industry
- Max
- 34.53%
- Q3
- 19.38%
- Median
- 9.52%
- Q1
- 4.86%
- Min
- -7.58%
PHG has a negative Return on Equity of -0.18%. This indicates the company is generating a loss for its shareholders, which can be a result of unprofitability or negative shareholder equity and is often a sign of financial distress.
SNY
14.92%
Pharmaceuticals Industry
- Max
- 38.59%
- Q3
- 19.84%
- Median
- 11.90%
- Q1
- 5.63%
- Min
- -9.96%
SNY’s Return on Equity of 14.92% is on par with the norm for the Pharmaceuticals industry, indicating its profitability relative to shareholder equity is typical for the sector.
Net Profit Margin (TTM)
PHG
0.90%
Health Care Equipment & Supplies Industry
- Max
- 23.34%
- Q3
- 13.06%
- Median
- 9.53%
- Q1
- 5.96%
- Min
- -3.87%
Falling into the lower quartile for the Health Care Equipment & Supplies industry, PHG’s Net Profit Margin of 0.90% indicates weaker profitability. This means the company retains a smaller portion of each dollar in sales as profit compared to its competitors.
SNY
20.51%
Pharmaceuticals Industry
- Max
- 34.51%
- Q3
- 17.73%
- Median
- 12.12%
- Q1
- 5.99%
- Min
- -7.73%
A Net Profit Margin of 20.51% places SNY in the upper quartile for the Pharmaceuticals industry, signifying strong profitability and more effective cost management than most of its peers.
Operating Profit Margin (TTM)
PHG
6.11%
Health Care Equipment & Supplies Industry
- Max
- 29.44%
- Q3
- 17.80%
- Median
- 13.95%
- Q1
- 8.73%
- Min
- -3.56%
PHG’s Operating Profit Margin of 6.11% is in the lower quartile for the Health Care Equipment & Supplies industry. This indicates weaker profitability from core operations, which may stem from inefficiencies or competitive pressures on pricing.
SNY
19.08%
Pharmaceuticals Industry
- Max
- 41.53%
- Q3
- 23.00%
- Median
- 16.24%
- Q1
- 9.24%
- Min
- -6.94%
SNY’s Operating Profit Margin of 19.08% is around the midpoint for the Pharmaceuticals industry, indicating that its efficiency in managing core business operations is typical for the sector.
Profitability at a Glance
| Symbol | PHG | SNY |
|---|---|---|
| Return on Equity (TTM) | -0.18% | 14.92% |
| Return on Assets (TTM) | -0.08% | 8.49% |
| Net Profit Margin (TTM) | 0.90% | 20.51% |
| Operating Profit Margin (TTM) | 6.11% | 19.08% |
| Gross Profit Margin (TTM) | 43.85% | 71.85% |
Financial Strength
Current Ratio (MRQ)
PHG
1.26
Health Care Equipment & Supplies Industry
- Max
- 4.90
- Q3
- 3.05
- Median
- 2.14
- Q1
- 1.49
- Min
- 0.86
PHG’s Current Ratio of 1.26 falls into the lower quartile for the Health Care Equipment & Supplies industry. This indicates a tighter liquidity situation and a more constrained capacity to handle short-term debt than many of its competitors.
SNY
1.27
Pharmaceuticals Industry
- Max
- 4.49
- Q3
- 2.77
- Median
- 1.74
- Q1
- 1.26
- Min
- 0.11
SNY’s Current Ratio of 1.27 aligns with the median group of the Pharmaceuticals industry, indicating that its short-term liquidity is in line with its sector peers.
Debt-to-Equity Ratio (MRQ)
PHG
0.81
Health Care Equipment & Supplies Industry
- Max
- 1.49
- Q3
- 0.71
- Median
- 0.45
- Q1
- 0.14
- Min
- 0.00
PHG’s leverage is in the upper quartile of the Health Care Equipment & Supplies industry, with a Debt-to-Equity Ratio of 0.81. While this approach can boost equity growth, it also exposes the company to greater financial vulnerability.
SNY
0.32
Pharmaceuticals Industry
- Max
- 2.44
- Q3
- 1.07
- Median
- 0.42
- Q1
- 0.11
- Min
- 0.00
SNY’s Debt-to-Equity Ratio of 0.32 is typical for the Pharmaceuticals industry, indicating its use of leverage is in line with the sector norm. This suggests a balanced approach to its capital structure.
Interest Coverage Ratio (TTM)
PHG
1.41
Health Care Equipment & Supplies Industry
- Max
- 58.29
- Q3
- 25.56
- Median
- 9.06
- Q1
- 3.60
- Min
- -28.92
In the lower quartile for the Health Care Equipment & Supplies industry, PHG’s Interest Coverage Ratio of 1.41 indicates a tighter cushion for servicing debt, suggesting less financial flexibility than many of its competitors.
SNY
22.06
Pharmaceuticals Industry
- Max
- 103.95
- Q3
- 44.18
- Median
- 9.83
- Q1
- 2.82
- Min
- -42.71
SNY’s Interest Coverage Ratio of 22.06 is positioned comfortably within the norm for the Pharmaceuticals industry, indicating a standard and healthy capacity to cover its interest payments.
Financial Strength at a Glance
| Symbol | PHG | SNY |
|---|---|---|
| Current Ratio (MRQ) | 1.26 | 1.27 |
| Quick Ratio (MRQ) | 0.81 | 0.94 |
| Debt-to-Equity Ratio (MRQ) | 0.81 | 0.32 |
| Interest Coverage Ratio (TTM) | 1.41 | 22.06 |
Growth
Revenue Growth
EPS Growth
Dividend
Dividend Yield (TTM)
PHG
0.00%
Health Care Equipment & Supplies Industry
- Max
- 4.05%
- Q3
- 1.76%
- Median
- 0.71%
- Q1
- 0.00%
- Min
- 0.00%
PHG’s Dividend Yield of 0.00% is consistent with its peers in the Health Care Equipment & Supplies industry, providing a dividend return that is standard for its sector.
SNY
4.56%
Pharmaceuticals Industry
- Max
- 6.98%
- Q3
- 3.32%
- Median
- 2.13%
- Q1
- 0.14%
- Min
- 0.00%
With a Dividend Yield of 4.56%, SNY offers a more attractive income stream than most of its peers in the Pharmaceuticals industry, signaling a strong commitment to shareholder returns.
Dividend Payout Ratio (TTM)
PHG
0.42%
Health Care Equipment & Supplies Industry
- Max
- 160.00%
- Q3
- 72.47%
- Median
- 27.49%
- Q1
- 0.00%
- Min
- 0.00%
PHG’s Dividend Payout Ratio of 0.42% is within the typical range for the Health Care Equipment & Supplies industry, suggesting a balanced approach between shareholder payouts and company reinvestment.
SNY
52.56%
Pharmaceuticals Industry
- Max
- 165.20%
- Q3
- 90.59%
- Median
- 49.13%
- Q1
- 28.91%
- Min
- 0.00%
SNY’s Dividend Payout Ratio of 52.56% is within the typical range for the Pharmaceuticals industry, suggesting a balanced approach between shareholder payouts and company reinvestment.
Dividend at a Glance
| Symbol | PHG | SNY |
|---|---|---|
| Dividend Yield (TTM) | 0.00% | 4.56% |
| Dividend Payout Ratio (TTM) | 0.42% | 52.56% |
Valuation
Price-to-Earnings Ratio (TTM)
PHG
140.05
Health Care Equipment & Supplies Industry
- Max
- 73.48
- Q3
- 51.69
- Median
- 34.31
- Q1
- 25.74
- Min
- 11.47
At 140.05, PHG’s P/E Ratio is exceptionally high, exceeding the typical maximum for the Health Care Equipment & Supplies industry. This suggests the stock may be significantly overvalued compared to its peers and implies high market expectations that could be difficult to meet.
SNY
9.57
Pharmaceuticals Industry
- Max
- 42.51
- Q3
- 26.88
- Median
- 19.11
- Q1
- 15.12
- Min
- 0.00
In the lower quartile for the Pharmaceuticals industry, SNY’s P/E Ratio of 9.57 suggests the stock may be undervalued compared to its peers, potentially presenting an attractive entry point for investors.
Price-to-Sales Ratio (TTM)
PHG
1.26
Health Care Equipment & Supplies Industry
- Max
- 9.53
- Q3
- 5.26
- Median
- 3.39
- Q1
- 2.13
- Min
- 0.00
In the lower quartile for the Health Care Equipment & Supplies industry, PHG’s P/S Ratio of 1.26 indicates its revenue is valued more conservatively than most of its peers. This could present a compelling opportunity if the market has overlooked its sales-generating capabilities.
SNY
1.96
Pharmaceuticals Industry
- Max
- 7.55
- Q3
- 4.54
- Median
- 2.11
- Q1
- 1.52
- Min
- 0.00
SNY’s P/S Ratio of 1.96 aligns with the market consensus for the Pharmaceuticals industry. This suggests its valuation, based on sales, is seen as standard and is on par with its competitors.
Price-to-Book Ratio (MRQ)
PHG
1.89
Health Care Equipment & Supplies Industry
- Max
- 10.85
- Q3
- 5.98
- Median
- 3.48
- Q1
- 2.43
- Min
- 0.69
PHG’s P/B Ratio of 1.89 is in the lower quartile for the Health Care Equipment & Supplies industry. From a value investing perspective, this is favorable, as it suggests the stock is trading at a discount to its net asset value and may offer a greater margin of safety.
SNY
1.44
Pharmaceuticals Industry
- Max
- 9.78
- Q3
- 4.96
- Median
- 2.23
- Q1
- 1.46
- Min
- 0.60
SNY’s P/B Ratio of 1.44 is in the lower quartile for the Pharmaceuticals industry. From a value investing perspective, this is favorable, as it suggests the stock is trading at a discount to its net asset value and may offer a greater margin of safety.
Valuation at a Glance
| Symbol | PHG | SNY |
|---|---|---|
| Price-to-Earnings Ratio (TTM) | 140.05 | 9.57 |
| Price-to-Sales Ratio (TTM) | 1.26 | 1.96 |
| Price-to-Book Ratio (MRQ) | 1.89 | 1.44 |
| Price-to-Free Cash Flow Ratio (TTM) | 14.66 | 10.47 |